LAE-32
From Wikipedia, the free encyclopedia
 |
This article does not cite any sources. (December 2009) (Learn how and when to remove this template message) |
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| Pharmacokinetic data | |
| Metabolism | hepatic |
| Excretion | renal |
| Identifiers | |
|
Systematic (IUPAC) name: (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
|
|
| Synonyms | LAE, Lysergic acid ethylamide, d-lysergic acid ethylamide, d-ethyllysergamide, |
| CAS Number | 478-99-9  |
| PubChem (CID) | 101704 |
| ChemSpider | 19975296 |
| Chemical and physical data | |
| Formula | C18H21N3O |
| Molar mass | 295.378 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.
It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but in schizophrenic people it allows them to remain indifferent to their disorder.[1]
References[edit]
 |
This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
